Skip to main content
    P

    Pacific Biosciences of California (PACB)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $1.84
    -0.12 (-6.12%)

    Market Cap: $611.98M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Pacific Biosciences of California (PACB) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Pacific Biosciences of California (PACB) to earn -$0.49 per share in the fiscal year ending Dec 31, 2026, on revenue of $157.48M. Of 8 analysts, 4 rate the stock Buy or Strong Buy, 3 Hold and 1 Sell or Strong Sell, for a consensus of Hold. Over the last 30 days, 0 estimates for the fiscal year ending Dec 31, 2026 were revised up and 1 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 8 ratings average 2.75, inside the Hold band from 2.5 up to 3.5. Buy and Strong Buy make up 50% of the ratings.

    RatingAnalystsShare
    Strong Buy00.0%
    Buy450.0%
    Hold337.5%
    Sell00.0%
    Strong Sell112.5%
    Consensus
    Hold
    Total analysts
    8

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates rise 13.1%.

    Fiscal year ending Dec 31, 2026
    -$0.49
    EPS consensus, revenue $157.48M
    Fiscal year ending Dec 31, 2027
    -$0.40
    EPS consensus, revenue $178.09M
    Next report
    Feb 9, 2027
    Estimated

    EPS range

    Revenue range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$0.49-$0.51 to -$0.485$157.48M$156.20M to $158.80M7
    Dec 31, 2027-$0.40-$0.52 to -$0.356$178.09M$171.00M to $189.00M7

    Quarterly Estimates

    The EPS consensus rises from -$0.13 for the quarter ending Dec 31, 2026 to -$0.10 for the quarter ending Mar 31, 2027.

    EPS range

    Revenue range

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$0.13-$0.13 to -$0.1110$42.55M$38.81M to $49.35M10
    Mar 31, 2027-$0.10-$0.13 to -$0.095$40.62M$38.80M to $42.29M6

    Estimate Revisions

    Across the 3 periods below, the last 30 days brought 0 upward and 5 downward EPS revisions. Cuts outnumber raises in every period.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202601
    Fiscal year ending Dec 31, 202702
    Quarter ending Mar 31, 202702

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$0.51.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026-$0.49-$0.52-$0.52-$0.51-$0.51N/A
    Fiscal year ending Dec 31, 2027-$0.40-$0.42-$0.42-$0.40-$0.40N/A
    Quarter ending Mar 31, 2027-$0.10-$0.11-$0.11-$0.11-$0.11N/A

    Frequently Asked Questions About PACB

    What is the PACB stock forecast?

    Consensus analyst estimates put Pacific Biosciences of California's EPS at -$0.49 for the fiscal year ending Dec 31, 2026, on revenue of $157.48M. The consensus rating from 8 analysts is Hold.

    How do analysts rate PACB stock?

    Of 8 analysts covering Pacific Biosciences of California, 0 rate it Strong Buy, 4 Buy, 3 Hold, 0 Sell and 1 Strong Sell, for a consensus of Hold.

    What EPS do analysts expect from PACB next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.49, with estimates from -$0.51 to -$0.48 from 5 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.40, with estimates from -$0.52 to -$0.35 from 6 analysts.

    What revenue do analysts expect from Pacific Biosciences of California next year?

    For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $157.48M, with estimates from $156.20M to $158.80M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $178.09M, with estimates from $171.00M to $189.00M.

    How many analysts cover PACB?

    8 analysts rate Pacific Biosciences of California stock, and 5 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.